Keywords: Ferring, Lysteda, Xanodyne, Zipsor, Licensing
Ferring acquires Lysteda from Xanodyne, which aims to focus on pain sector; second deal for the firms
Article | 11 May 2010
Switzerland-based Ferring Pharmaceuticals has entered an agreement that will expand its Women's Health product portfolio with the acquisition of the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
